FAQ: Which US public health concerns cystatin C testing help alleviate?
04. Mar 2020 |
5 min read
In this segment we will answer questions our Product Manager for cystatin C and Product Specialist in the US get about cystatin C at exhibitions, conferences and client meetings. Today’s question is “Which US public health concerns can cystatin C testing help alleviate?".
Which US public health concerns can cystatin C testing help alleviate?
Chronic kidney disease (CKD) is a growing public health issue with an estimated prevalence of 15% among U.S adults . The high cost of treating end stage renal disease (ESRD) suggests that slowing CKD progression and developing targeted approaches to disease management should be a priority for healthcare systems in the US. Cystatin C testing could ensure that these priorities are met by enabling an unbiased assessment of renal function, which is central to diagnosis and management of kidney disease. In fact, cystatin C has been used to define a preclinical period of reduced kidney function that precedes conventional creatinine-based diagnosis of CKD by 10+ years [2,3].
Incorporating cystatin C testing into CKD patient care could also alleviate racial disparities in kidney disease outcomes, by allowing for assessment of renal function independent of a patient’s muscle mass. One such disparity is that African Americans who are diagnosed with CKD are three times as likely as Caucasians to develop ESRD . Bias inherent in equations used to estimate kidney function solely via creatinine is a significant contributor to this public health issue.
The CKD-EPI equation regarded as the “best overall index for kidney function,” accounts for the higher muscle mass observed in African Americans with a 15.9% increase in eGFR over that of their Caucasians counterparts . For a patient with below-average muscle mass, such an increase could delay diagnosis of CKD and interventions against progression into ESRD. In later stages of the disease, a 15.9% increase could also mean that an African American patient becomes eligible for dialysis or a kidney transplant much later than a Caucasian patient with the same prognosis.
Do you want to know more about Gentian's cystatin C immunoassay or cystatin C in general? Send an email firstname.lastname@example.org fill out the form below and our Product Manager for cystatin C will get in touch.
Shlipak, M. G., Matsushita, K., Ärnlöv, J., Inker, L. A., Katz, R., Polkinghorne, K. R., ... & Levey, A. S. (2013). Cystatin C versus creatinine in determining risk based on kidney function. New England Journal of Medicine, 369(10), 932-943.
Parsons, T. (2013, September 4). Relationship of Kidney Function Estimates to Risk Improves by Measuring Cystatin C in the Blood. Retrieved April 6, 2020, from https://www.jhsph.edu/news/news-releases/2013/coresh-cystatin-c.html
HEALTHCARE, A. D. I. (2017). Chronic kidney disease in African Americans: Puzzle pieces are falling into place. Cleveland Clinic journal of medicine, 84(11), 855.
Levey, A. S., Stevens, L. A., Schmid, C. H., Zhang, Y. L., Castro, A. F., Feldman, H. I., ... & Coresh, J. (2009). A new equation to estimate glomerular filtration rate. Annals of internal medicine, 150(9), 604-612.
Gentian Cystatin C
Gentian’s cystatin C immunoassaywas launched in 2006. It is a Particle-Enhanced Turbidimetric Immunoassay (PETIA) for in vitro testing of cystatin C in human plasma and serum samples. The test has documented high inter-instrument accuracy on a wide range of clinical chemistry analysers and can be performed in as little as 10 minutes.